EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeted delivery of HSP90 inhibitors for efficient therapy of CD44-positive acute myeloid leukemia and solid tumor-colon cancer

Lejiao Jia, Huatian Yang, Yue Liu, Ying Zhou, Guosheng Li, Qian Zhou, Yan Xu, Zhiping Huang, Feng Ye, Jingjing Ye, Anchang Liu, Chunyan Ji

Journal of Nanobiotechnology · 2024

DOI: 10.1186/s12951-024-02460-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nanobiotechnology, 2024. Verfasst von Lejiao Jia und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Cheeloo College of Medicine, Qilu Hospital, Shandong University, Jinan, Shandong, 250012, China. Hauptthemen laut MEDLINE: HSP90 Heat-Shock Proteins, Hyaluronan Receptors, Colonic Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Young Taishan Scholar Program, the Natural Science Foundation of Shandong Province, the Distinguished Taishan Scholars Plan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heat shock protein 90 (HSP90) is overexpressed in numerous cancers, promotes the maturation of numerous oncoproteins and facilitates cancer cell growth. Certain HSP90 inhibitors have entered clinical trials. Although less than satisfactory clinical effects or insurmountable toxicity have compelled these trials to be terminated or postponed, these results of preclinical and clinical studies demonstrated that the prospects of targeting therapeutic strategies involving HSP90 inhibitors deserve enough attention. Nanoparticulate-based drug delivery systems have been generally supposed as one of the most promising formulations especially for targeting strategies. However, so far, no active targeting nano-formulations have succeeded in clinical translation, mainly due to complicated preparation, complex formulations leading to difficult industrialization, incomplete biocompatibility or nontoxicity. In this study, HSP90 and CD44-targeted A6 peptide functionalized biomimetic nanoparticles (A6-NP) was designed and various degrees of A6-modification on nanoparticles were fabricated to evaluate targeting ability and anticancer efficiency. With no excipients, the hydrophobic HSP90 inhibitor G2111 and A6-conjugated human serum albumin could self-assemble into nanoparticles with a uniform particle size of approximately 200 nm, easy fabrication, well biocompatibility and avoidance of hepatotoxicity. Besides, G2111 encapsulated in A6-NP was only released less than 5% in 12 h, which may avoid off-target cell toxicity before entering into cancer cells. A6 peptide modification could significantly enhance uptake within a short time. Moreover, A6-NP continues to exert the broad anticancer spectrum of Hsp90 inhibitors and displays remarkable targeting ability and anticancer efficacy both in hematological malignancies and solid tumors (with colon tumors as the model cancer) both in vitro and in vivo. Overall, A6-NP, as a simple, biomimetic and active dual-targeting (CD44 and HSP90) nanomedicine, displays high potential for clinical translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HSP90 Heat-Shock ProteinsHyaluronan ReceptorsColonic NeoplasmsAntineoplastic AgentsLeukemia, Myeloid, AcuteHumansAnimalsCell Line, TumorMiceNanoparticlesDrug Delivery SystemsMice, NudeMice, Inbred BALB CPeptides

Stichwörter der Autor:innen

Active targeting nanoparticlesAcute myeloid leukemiaCD44Heat shock protein 90Solid tumor

Substanzen

HSP90 Heat-Shock ProteinsHyaluronan ReceptorsAntineoplastic AgentsCD44 protein, humanPeptides

Autor:innen und Institutionen

  • Department of Pharmacy, Cheeloo College of Medicine, Qilu Hospital, Shandong University, Jinan, Shandong, 250012, China.
  • Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.
  • Department of Pharmacy, Affiliated Hospital of Shandong University of Traditional Chinese Medicine (TCM), Jinan, Shandong, 250014, China.
  • Department of Hematology, Cheeloo College of Medicine, Qilu Hospital, Shandong University, Jinan, Shandong, 250012, China.
  • Key Laboratory of Chemical Biology of Ministry of Education, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.
  • Department of Hematology, Cheeloo College of Medicine, Qilu Hospital, Shandong University, Jinan, Shandong, 250012, China. yejingjing@sdu.edu.cn.

Förderung

  • the Young Taishan Scholar Program
  • the Natural Science Foundation of Shandong Province
  • the Distinguished Taishan Scholars Plan
  • the Distinguished Taishan Scholars in Climbing Plan
  • the National Natural Science Foundation of China
  • the Fundamental Research Funds for the Central Universities
  • the Independently Cultivate Innovative Teams of Jinan, Shandong Province

Zitieren

APA

Jia, L., Yang, H., Liu, Y., Zhou, Y., Li, G., Zhou, Q., Xu, Y., Huang, Z., Ye, F., Ye, J., Liu, A., & Ji, C. (2024). Targeted delivery of HSP90 inhibitors for efficient therapy of CD44-positive acute myeloid leukemia and solid tumor-colon cancer. Journal of Nanobiotechnology. https://doi.org/10.1186/s12951-024-02460-1

Vancouver

Jia L, Yang H, Liu Y, Zhou Y, Li G, Zhou Q, et al. Targeted delivery of HSP90 inhibitors for efficient therapy of CD44-positive acute myeloid leukemia and solid tumor-colon cancer. Journal of Nanobiotechnology. 2024. doi:10.1186/s12951-024-02460-1

BibTeX
@article{Jia2024,
  author = {Jia, Lejiao and Yang, Huatian and Liu, Yue and Zhou, Ying and Li, Guosheng and Zhou, Qian and Xu, Yan and Huang, Zhiping and Ye, Feng and Ye, Jingjing and Liu, Anchang and Ji, Chunyan},
  title = {Targeted delivery of HSP90 inhibitors for efficient therapy of CD44-positive acute myeloid leukemia and solid tumor-colon cancer},
  journal = {Journal of Nanobiotechnology},
  year = {2024},
  doi = {10.1186/s12951-024-02460-1}
}
Kostenlos starten →